
CAN-2409/Prodrug Improve OS in ICI-Resistant, Advanced NSCLC
CAN-2409, a multimodal biological immunotherapy candidate engineered to deliver the herpes simplex virus thymidine kinase to a patient’s tumor, produced improved overall survival (OS) in patients with advanced non–small cell lung cancer (NSCLC) who had an …